Pasotti C, Zoppi A, Capra A, Rebagliati M, Fogari R
Int J Clin Pharmacol Ther Toxicol. 1986 Aug;24(8):448-52.
Forty-five hypertensive patients (I-II WHO), after two weeks wash out, were randomly allocated to receive 100 mg/day atenolol, 200 mg/day metoprolol and 10 mg/day mepindolol for three months, in order to evaluate their possible effect on lipid metabolism. Plasma triglyceride levels were increased by the three drug treatments; the increase was, however, greater after mepindolol. Total cholesterol was unchanged by atenolol, increased by metoprolol and decreased by mepindolol. HDL-cholesterol was unchanged by atenolol, decreased by metoprolol and increased by mepindolol, whereas LDL-cholesterol was increased by atenolol, unchanged by metoprolol and decreased by mepindolol. Therefore, the LDL/HDL ratio was decreased by mepindolol (from 3.15 +/- 1.71 to 2.92 +/- 1.17) and increased by atenolol and metoprolol. The results show that the treatment with atenolol, metoprolol and mepindolol does not significantly affect the lipid levels suggesting that cardioselective beta-blockers as well as those with ISA have no untoward effect on lipid metabolism.
45例高血压患者(WHO分级I-II级),经过两周洗脱期后,被随机分配接受为期三个月的治疗,分别为每日服用100毫克阿替洛尔、200毫克美托洛尔和10毫克甲吲哚洛尔,以评估它们对脂质代谢的可能影响。三种药物治疗均使血浆甘油三酯水平升高;然而,甲吲哚洛尔治疗后的升高幅度更大。阿替洛尔对总胆固醇无影响,美托洛尔使其升高,甲吲哚洛尔使其降低。阿替洛尔对高密度脂蛋白胆固醇无影响,美托洛尔使其降低,甲吲哚洛尔使其升高,而低密度脂蛋白胆固醇则是阿替洛尔使其升高,美托洛尔无影响,甲吲哚洛尔使其降低。因此,甲吲哚洛尔降低了低密度脂蛋白/高密度脂蛋白比值(从3.15±1.71降至2.92±1.17),而阿替洛尔和美托洛尔则使其升高。结果表明,阿替洛尔、美托洛尔和甲吲哚洛尔治疗对血脂水平无显著影响,提示心脏选择性β受体阻滞剂以及具有内在拟交感活性的β受体阻滞剂对脂质代谢无不良影响。